The Advanced Regenerative Bio Act framework international patients should understand first
Quick answer
Stem cell injection for kidney disease in South Korea sits under the advanced regenerative medicine framework: cells must be manufactured in a licensed GMP facility, and administration must fall within an approved clinical study or case-by-case review, not a freely advertised commercial service.
The first point is the line between research and treatment. Clinical studies pass an ethics committee and the regulator, with defined eligibility criteria and adverse-event reporting, so participants are better protected than buyers of an ordinary service.
The second point is manufacturing: patient cells must come from a licensed facility with batch records, contamination testing and viability results, and patients may ask for a summary of that documentation.
The third point is advertising: claims of a cure or of ending dialysis are red flags both legally and medically. Compliant clinics communicate cautiously and always state the uncertainty.
Sometimes, depending on eligibility criteria and whether follow-up after returning home is feasible.
Recent labs with eGFR and UACR history, a medication list and a nephrologist summary.
No. Regulation governs safety and process, not proof of efficacy.
Keep a contact channel with the Korean team and inform your local nephrologist immediately with the treatment records.
It may reflect a low cell count or an unregulated process; ask for written details.
5 points • reviewed 2026-09-02
Reviewed and last updated: 2026-09-02
5 sources • every claim is traceable
https://www.ehlbio.co.kr
https://www.mfds.go.kr/eng/index.do
https://www.mohw.go.kr/eng/
https://pubmed.ncbi.nlm.nih.gov/
https://www.medicalkorea.or.kr/
Last updated: 2026-09-02 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categories